Genprex shares surge 14.55% pre-market after positive preclinical diabetes gene therapy data.

Genprex Inc. (GNPX) surged 14.55% in premarket trading following the announcement of positive preliminary preclinical data for its diabetes gene therapy GPX-002 in Type 2 diabetic animal studies, reported 4 days prior. The update, alongside ongoing advancements in its Acclaim-1 and Acclaim-3 lung cancer clinical trials, reinforced investor confidence in the company’s therapeutic pipeline. Recent news also highlighted new patents for combining Reqorsa® gene therapy with PD-L1/PD-1 antibodies, strengthening intellectual property protections and potential treatment applications. These developments, coupled with expanded clinical trial sites and collaborations, underscored Genprex’s progress in oncology and metabolic disease research, aligning with the stock’s upward momentum.